Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.59 |
| ▸ | CA12 | O43570 | 1/20 | 0.59 |
| ▸ | CA1 | P00915 | 1/20 | 0.59 |
| ▸ | CA2 | P00918 | 1/20 | 0.59 |
| ▸ | CA3 | P07451 | 1/20 | 0.59 |
| ▸ | CA4 | P22748 | 1/20 | 0.59 |
| ▸ | CA6 | P23280 | 1/20 | 0.59 |
| ▸ | CA5A | P35218 | 1/20 | 0.59 |
| ▸ | CA7 | P43166 | 1/20 | 0.59 |
| ▸ | CA9 | Q16790 | 1/20 | 0.59 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.59 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.59 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.59 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.41 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.41 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.41 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.41 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.41 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.40 |
| ▸ | BRD4 | O60885 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12156956 | 0.88 | LMNA (0.61) | LMNACA12CA1CA2CA3 | |
| SCHEMBL14834787 | 0.82 | LMNA (0.55) | LMNACA12CA1CA2CA3 | |
| SCHEMBL11471685 | 0.81 | LMNA (0.59) | LMNACA12CA1CA2CA3 | |
| SCHEMBL14163977 | 0.81 | LMNA (0.54) | LMNACA12CA1CA2CA3 | |
| SCHEMBL13092672 | 0.80 | LMNA (0.54) | LMNACA12CA1CA2CA3 | |
| SCHEMBL13657207 | 0.80 | LMNA (0.53) | LMNACA12CA1CA2CA3 | |
| SCHEMBL4398011 | 0.79 | LMNA (0.53) | LMNACA12CA1CA2CA3 | |
| SCHEMBL20851074 | 0.79 | LMNA (0.53) | LMNACA12CA1CA2CA3 | |
| SCHEMBL8259691 | 0.79 | LMNA (0.41) | LMNACA12CA1CA2CA3 | |
| SCHEMBL6962028 | 0.78 | LMNA (0.51) | LMNACA12CA1CA2CA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118390079-A | Method for preparing (S) -2- (2-oxo-pyrrolidine-1-yl) butyric acid by electrocatalytic oxidation of volcanic nano-carbon loaded platinum catalyst | 衢州市浙工大生态工业创新研究院 | 2024-07-26 | — | — | CN | claimed |
| CN-118390079-A | Method for preparing (S) -2- (2-oxo-pyrrolidine-1-yl) butyric acid by electrocatalytic oxidation of volcanic nano-carbon loaded platinum catalyst | 衢州市浙工大生态工业创新研究院 | 2024-07-26 | — | — | CN | disclosed |
| CN-118390079-A | Method for preparing (S) -2- (2-oxo-pyrrolidine-1-yl) butyric acid by electrocatalytic oxidation of volcanic nano-carbon loaded platinum catalyst | 衢州市浙工大生态工业创新研究院 | 2024-07-26 | — | — | CN | disclosed |
| US-9290486-B1 | Compositions and methods for the treatment of epilepsy | CELLIX BIO PRIVATE LIMITED (IN) | 2016-03-22 | — | — | US | disclosed |
| US-9290486-B1 | Compositions and methods for the treatment of epilepsy | CELLIX BIO PRIVATE LIMITED (IN) | 2016-03-22 | — | — | US | disclosed |
| US-20080194840-A1 | Process for Preparing Levetiracetam and Racemization of (R)- and (S)-2-Amino Butynamide and the Corresponding Acid Derivatives | RUBAMIN LABORATORIES LIMITED (IN) | 2008-08-14 | — | — | US | disclosed |
| US-20080194840-A1 | Process for Preparing Levetiracetam and Racemization of (R)- and (S)-2-Amino Butynamide and the Corresponding Acid Derivatives | RUBAMIN LABORATORIES LIMITED (IN) | 2008-08-14 | — | — | US | disclosed |
| WO-2008077035-A2 | PROCESSES FOR THE PREPARATION OF LEVETIRACETAM | DR. REDDY'S LABORATORIES LTD. (IN) | 2008-06-26 | — | — | WO | disclosed |
| US-20080146819-A1 | Process for Preparing Levetiracetam | RUBAMIN LIMITED (IN) | 2008-06-19 | — | — | US | disclosed |
| US-20080146819-A1 | Process for Preparing Levetiracetam | RUBAMIN LIMITED (IN) | 2008-06-19 | — | — | US | disclosed |
| WO-2006103696-A2 | PROCESS FOR PREPARING LEVETIRACETAM AND RACEMIZATION OF (R)- AND (S)-2-AMINO BUTYNAMIDE AND THE CORRESPONDING ACID DERIVATIVES | RUBAMIN LABORATORIES LIMITED (IN) | 2006-10-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080194840-A1 | Process for Preparing Levetiracetam and Racemization of (R)- and (S)-2-Amino Butynamide and the Corresponding Acid Derivatives | BCAT2, ADH1C, ABAT | LMNA 3428/4885CA12 937/4885CA1 146/4885 |
| US-20080146819-A1 | Process for Preparing Levetiracetam | ADH1C, ADH1A, ADH5 | LMNA 3024/4885CA12 810/4885CA1 124/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.